ಶ್ವಾಸಕೋಶದ ಕ್ಯಾನ್ಸರ್ (ನಾನ್-ಸ್ಮಾಲ್ ಸೆಲ್)
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
ಎಲ್ಲಿಗೆ ಹೋಗಬೇಕು
ಈ trial ಗೆ 1 ಆಸ್ಪತ್ರೆ ರೋಗಿಗಳನ್ನು ಸೇರಿಸಿಕೊಳ್ಳುತ್ತಿದೆ.
ರಿಜಿಸ್ಟ್ರಿ ಸಾರಾಂಶ (ತಾಂತ್ರಿಕ)
Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases. Brain radiotherapy/surgery is the standard treatment in brain metastases especially symptomatic metastases, however, the role of local treatment especially in driver mutation-positive non-small cell lung cancer with asymptomatic brain metastases is being questioned given their potential side effects. No randomized trial has shown the superiority of early vs delayed cranial RT in asymptomatic BM of driver mutated NSCLC.
Sponsor: ಟಾಟಾ ಮೆಮೋರಿಯಲ್ ಹಾಸ್ಪಿಟಲ್
NCT05236946 on ClinicalTrials.gov
Last updated on the registry 10 Sep 2025 · read by us 20 Oct 2026